Denis Patrick, PHD is a Partner of Pfizer Ventures and Vice President, Worldwide Business Development. Denis capitalizes upon his experience in evaluating external opportunities to identify and manage equity investments. He currently has responsibility for Pfizer’s investments in AnTolRx, Anaveon, Aquinnah Pharmaceuticals, DEM Biopharma, EvolveImmune Therapeutics, FoRx Therapeutics, Kestrel Therapeutics, MISSION Therapeutics, and Palleon Pharma.  His prior investment responsibilities include Bolt Biotherapeutics (BOLT), eFFECTOR Therapeutics (EFTR), Encycle, Simcha, Metabomed and NextCure (NXTC).
Previously, Denis served as Head of Oncology Licensing for Worldwide R&D at Pfizer from 2010 to 2018.  In this capacity some of his recent executed agreements included acquisitions of Medivation and BIND Therapeutics, and research licenses with CytomX, Stemcentrx, iTeos, BioAtla, Western Oncolytics, eFFECTOR, Cancer Research Therapeutics and Arvinas.  Prior to coming to Pfizer, Denis worked for several large pharma oncology organizations, including Merck, DuPont Pharma, and GSK. He contributed significantly to several oncology drug discovery efforts that led to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib.  
Denis received his BS in Biochemistry from SUNY at Stony Brook, MS in Biology from UCSD and PhD in Biochemistry from the University of Pennsylvania.

Email: [email protected]